A PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PRIOR B CELL MATURATION ANTIGEN-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Daniel Sherbenou
Study ID
Protocol Number: 22-0931
More information available at ClinicalTrials.gov: NCT05535244
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers